An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD)

Overview

The purpose of the study is to assess safety and tolerability of a Phase I drug, INBRX-101 in patients with alpha-1 antitrypsin deficiency (AATD).

Description

Here at IU Health, we are recruiting for clinical trial to study the effects of a new drug on Alpha-1 Antitrypsin Deficiency (AATD).  All study procedures will take place at University Hospital at no cost to you.  You will be compensated for your time and effort.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions: Alpha-1 Antitrypsin Deficiency (AATD)
  • Age: Between 18 Years - 70 Years
  • Gender: Male or Female

Inclusion Criteria

AATD diagnosis, willing to undergo 2 bronchoscopies

Non-smoker

Willing to hold current AATD treatment until study ends (about 5 months).

Updated on 20 Nov 2022 . Study ID: TX10435
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center